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AntioxidantsAbstract There are numerous herbal medicines that have been introduced into psychiatric practice
because of greater compliance and milder side effects. Polygonum cuspidatum is a native Asian
plant; known for its medicinal properties and traditionally used in the treatment of neuropsychiatric
disorders, such as psychosocial stress, dementia and Parkinson’s disease. Resveratrol is the active
ingredient of P. cuspidatum. Researchers have suggested that the trans-isomer of resveratrol dem-
onstrates a variety of pharmacological activities including antioxidant, anti-inﬂammatory, hepatic
and neuroprotective properties. In this study we examined the hepatoprotective and antidepressant
effects of trans-resveratrol against ﬂuoxetine in an acute reserpine model of depression in rats. Main
methods: depression-like behaviors were induced by single reserpine intraperitoneal injection (6 mg/
kg, i.p.). Trans-resveratrol (15, 30 and 60 mg/kg bwt) and ﬂuoxetine (24 mg/kg bwt) were adminis-
tered orally for the following 3 days. Behavioral effects namely open ﬁeld test (OFT) and forced
swimming test (FST) and biochemical parameters namely neurotransmitters levels and antioxidant
contents were assessed. Liver histopathological examination was performed. Key ﬁndings: Results
revealed that resveratrol (60 mg/kg bwt) showed a potential hepatoprotective and an antidepres-
sant-like effects compared to those of ﬂuoxetine.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.1. Introduction
Depression is a common and invalidating mental illness affect-
ing approximately 2.5% of the general population. It has neg-ative social consequences in terms of reduced employment and
psychosocial impairment. Based on the World Health Organi-
zation surveys; it has been suggested to become the second lead-
ing cause of disability by 2020.1 Despite a steady increase in the
number of antidepressants over the years, the prevalence of the
disorder remains stable which may be due to unclear patho-
physiology or the inconsistent efﬁcacy of currently available
antidepressants with undesirable side effects. However, there
is a direct correlation between the catecholaminergic neuronal
systems and depression.2
192 R.F. Ahmed et al.Fluoxetine is a widely prescribed selective serotonin reup-
take inhibitor with antidepressant properties.3 However, it
has recently been postulated to induce liver damage and medi-
ates free radical reactions due to its ﬂuorine content.4
A variety of consumable plant-derived phytochemicals
exhibit nutraceutical properties because they produce physi-
ological beneﬁts and combat disease processes. Emerging
evidence suggests that widely accessible and safe organic
polyphenolic phytochemicals, in particular, treat depression
at much lower concentrations than clinical doses of classical
drugs.5
Resveratrol (3,5,40-trihydroxystilbene) is a polyphenolic
compound that has been detected in fruits and some ﬂowering
plants. It was ﬁrst isolated from the roots of white hellebore
(Veratrum grandiﬂorum O. Loes) in 1940 and later, in 1963
from the roots of Polygonum cuspidatum, a plant used in tradi-
tional Chinese and Japanese medicine. Other major dietary
sources containing resveratrol include grapes, wine, peanuts,
and peanut products. The ﬁrst real interest in this compound
came when in 1992 resveratrol was postulated to explain some
of the cardio-protective effects of red wine and was suggested
to be an important factor in the French Paradox, a term coined
to describe the observation that the French population has a
very low incidence of cardiovascular disease, despite a diet
high in saturated fat. Five years later, in 1997, resveratrol
was reported to work as a chemo-preventive agent, by the abil-
ity to inhibit carcinogenesis at multiple stages. Meanwhile, also
anti-inﬂammatory and antioxidant properties were identiﬁed
for resveratrol.6–9 Additionally, the protective role of resvera-
trol against a number of hepatic injuries (e.g. cholestasis) due
to oxidative damage of primary rat hepatocytes was reported
by several authors.10–12 Moreover, intraperitoneal administra-
tion of resveratrol in rats with ligated bile ducts maintained
antioxidant defenses and reduced liver oxidative damage and
ductular proliferation.13 Neuro-pharmacological activities
such as amelioration of learning and memory impairment
and neuroprotective properties have also been reported.14–17
The present study aimed to investigate the combined hepa-
toprotective and antidepressant effects of trans-resveratrol
against ﬂuoxetine in a reserpine model of depression in rats.
2. Materials and methods
2.1. Animals
Adult male Wister rats, weighing 130–150 g each, were pur-
chased from the animal house at the National Research
Centre (NRC, Giza, Egypt). All animals received care in
compliance with the guidelines of the animal care and use
committee of the NRC. Upon arrival, the animals were kept
in a quiet place, housed eight per cage and acclimatized to a
colony room with controlled ambient temperature
(22 ± 1 C), humidity (50 ± 10%) and a 12 h natural
light/dark cycle. They were fed a standard diet, water was
provided ad libitum and they were acclimated for 7 days
before entry into the subsequent study. They were allowed
free access to water and food throughout the period of
investigation. All the procedures described below were car-
ried out in accordance with the guidelines of the EU Direc-
tive 2010/63/EU for animal experiments. The experiments
were performed with 8 rats per treatment group accordingto a randomized schedule. In behavioral tests, animals in
every group were intermixed during the observation and
the observers were unaware of the treatment conditions.
2.2. Drugs and drug administration
Fluoxetine hydrochloride (Prozac 20 mg dispersible tablets,
Lilly, Spain), the tablets were freshly suspended in distilled
water prior to oral administration. Trans-resveratrol was
provided as a generous gift from Jing Tea LLC, it was pro-
vided as Harmoni-T micronized trans-resveratrol capsules
for ingestion. The powder in the capsules was freshly dis-
solved in distilled water just before oral administration.
Reserpine was a generous gift from Novartis co. Egypt, it
was provided as pure powder for injection and it was freshly
dissolved in a DMSO/saline mixture (0.1: 10 ml) before
intraperitoneal injection.
2.3. Experimental design
Rats were divided into six different groups (8 rats each) and
treated as follows; Group (1): normal control (DMSO/saline
group). Group (2): depressed group (reserpine group). Group
(3): receiving ﬂuoxetine (24 mg/kg, p.o.).4 Groups (4, 5 and
6): receiving trans-resveratrol (15, 30 and 60 mg/kg, p.o.).
2.4. Experimental procedure
Groups 2, 3, 4, 5 and 6 were administered reserpine (6 mg/kg,
i.p.) once on day one of the experiment. This dose results in
depression symptoms that persist for 72 h. after injection.18
Group (1) was administered DMSO/Saline i.p. injections on
the same day. Group (1) was kept in separate cages and had
free access to food and water till the end of the experiment.
All other groups received the corresponding drugs orally for
the following 3 days. On day number 2 behavioral tests,
namely open ﬁeld test (OFT) and forced swimming test
(FST) were performed. Twenty-four hours later, the rats were
killed by decapitation 30 min after the last drug ingestion.
Brain and liver tissues were isolated and each brain or liver
was washed with cold sterile physiological saline, blotted
between two damp ﬁlter papers and stored at 80 C for fur-
ther biochemical analysis. Parts of the liver tissues were iso-
lated in formalin and used for the histopathology.
2.5. Behavioral tests
2.5.1. Open ﬁeld test
The open ﬁeld test was carried out in a square wooden arena
(80 cm · 80 cm · 40 cm high) with red walls and white smooth
polished ﬂoor divided by black lines into 16 equal squares. The
test was performed under white light in a quiet room. Each rat
was placed at the same corner square and observed during
5 min. The ﬂoor and walls were cleaned after testing each
rat. The following parameters were recorded during the
5 min observation period; latency: time taken by each animal
till it starts moving in the arena, ambulation frequency: num-
ber of squares crossed by the animal, rearing frequency: num-
ber of times the animal stood stretched on its hind limbs with
or without forelimb support.19–21
Figure 1 Depression was induced by acute reserpine injection. Statistical analysis for the latency time was carried out by one way
ANOVA followed by Tukey HSD post hoc multiple comparison test. Statistical analysis for the ambulation and rearing frequencies was
carried out by non parametric K independent samples Kruskal–Wallis H test followed by Two-independent-samples Mann–Whitney U
test. Data were expressed as mean ± SEM, n= 8 rats/group. *, signiﬁcant from depressed control at P< 0.05; #, signiﬁcant from normal
control at P< 0.05.
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The forced swimming test was performed according to the
method described by Porsolt et al.22 Each rat was placed for
5 min in a cylindrical water tank (70 cm high, 40 cm diameter)
where, water level was about 40 cm and water temperature was
maintained at 23–25 C. The total duration of immobility of
each animal was recorded. The tank was emptied and washed
with fresh water ﬂush between each rat to remove any traces of
urine or feces.
2.6. Biochemical analysis
2.6.1. Determination of brain monoamine contents
Each brain tissue was weighed and homogenized in 75% aque-
ous HPLC grade methanol (10% w/v). The homogenate was
spun at 4000 r.p.m. for 10 min. and the supernatant was iso-
lated. Brain monoamines were detected by HPLC according
to the method described by Pagel et al.23
2.6.2. Determination of brain and liver MDA and GSH levels
Each brain or liver tissue was homogenized in ice-cold saline
(20% w/v).24 The homogenate was divided into 2 portions
for the determination of malondialdehyde (MDA) and reduced
glutathione (GSH) levels. The level of MDA was determined
according to the method of Ruiz-Larea et al.25 The level of
GSH was determined according to the method of Ellman mod-
iﬁed by Bulaj et al.26,27
2.7. Statistical analysis
Statistical analyses for the ambulation and rearing frequencies
were carried out by non parametric K independent samples
Kruskal–Wallis H test followed by two-independent-samplesMann–Whitney U test. Statistical analyses for the latency time
in the open ﬁeld test and the immobility duration in the forced
swimming test were carried out by one way analysis of vari-
ance (ANOVA) followed by Tukey HSD post hoc multiple
comparisons test. For all the other parameters, statistical anal-
yses were performed by one way ANOVA followed by the
Least Signiﬁcant Difference post hoc multiple comparisons
test (LSD test).
3. Results
3.1. Effect of trans-resveratrol on the open ﬁeld parameters
The results are represented in Fig. 1a and b. Depression-like
behavior induced by reserpine could be clearly demonstrated
by the signiﬁcant decrease in the activity of all rats compared
to vehicle control values. Trans-resveratrol (15, 30 and 60 mg/
kg, p.o.) dose dependently increased the rat activity signiﬁ-
cantly compared to the depressed control where, the latency
time was signiﬁcantly decreased at the three dose levels and
the ambulation frequency was normalized at the higher two
doses. Fluoxetine (24 mg/kg, p.o.) treatment normalized the
open ﬁeld parameters.
3.2. Effect of trans-resveratrol on the immobility duration in the
forced swimming test (FST)
Fig. 2 shows the effects of trans-resveratrol (15, 30 and 60 mg/
kg, p.o.) and ﬂuoxetine (24 mg/kg, p.o.) on the duration of
immobility in the forced swimming test. Post hoc analysis
revealed that trans-resveratrol, at doses of 15 and 30 mg/kg,
led to a dose-dependent reduction in the immobility period
as compared to the depressed control group. Resveratrol
Figure 2 Depression was induced by acute reserpine injection.
Statistical analysis was carried out by one way ANOVA followed
by Tukey HSD post hoc multiple comparison test. Data were
expressed as mean ± SEM, n= 8 rats/group. \, Signiﬁcant from
depressed control at P< 0.05; #, signiﬁcant from normal control
at P< 0.05.
Table 2 Effect of trans-resveratrol on the brain GSH and
MDA levels in depressed rats using the acute reserpine injection
model of depression.
Antioxidant parameter GSH
(lmol/g tissue)
MDA
(nmol/g tissue)
Groups
Normal control 2.38 ± 0.046 126.62 ± 2.33*
Depressed control 2.38 ± 0.071 249.14 ± 12.012#
Fluoxetine (24 mg/kg) 2.47 ± 0.077 129.61 ± 4.143*
Resveratrol (15 mg/kg) 2.46 ± 0.125 248.59 ± 11.72#
Resveratrol (30 mg/kg) 2.48 ± 0.141 172.98 ± 5.656*,#
Resveratrol (60 mg/kg) 2.53 ± 0.290 128.16 ± 4.847*
Depression was induced by acute reserpine injection. Statistical
analysis was carried out by one way ANOVA followed by LSD
post hoc multiple comparison test. Data were expressed as
mean ± SEM, n= 8 rats/group.
* Signiﬁcant from depressed control at P< 0.05.
# Signiﬁcant from normal control at P< 0.05.
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p.o.) normalized the immobility time.
3.3. Effect of trans-resveratrol on the neurotransmitter levels
The levels of monoamines detected are summarized in Table 1.
Statistics revealed that both serotonin and dopamine levels
were normalized after the administration of ﬂuoxetine
(24 mg/kg) and the three dose levels of trans-resveratrol.
Nor-epinephrine level was only normalized in case of trans-
resveratrol (60 mg/kg, p.o.) and ﬂuoxetine. The two lower
doses of trans-resveratrol had no effect on the nor-epinephrine
level compared to the depressed group.
3.4. Effect of trans-resveratrol on the brain GSH and MDA
levels
Results are represented in Table 2. Acute reserpine injection
signiﬁcantly increased the brain level of MDA compared to
the vehicle control group but had no effect on the GSH content.
Both ﬂuoxetine (24 mg/kg, p.o.) and trans-resveratrol (60 mg/
kg, p.o.) normalized the MDA level.Table 1 Effect of trans-resveratrol on the neurotransmitter levels
depression.
Neurotransmitter parameter Serotonin (lg/g tissue)
Groups
Normal control 0.220 ± 0.012*
Depressed control 0.182 ± 0.011#
Fluoxetine (24 mg/kg) 0.253 ± 0.008*,#
Resveratrol (15 mg/kg) 0.229 ± 0.008*
Resveratrol (30 mg/kg) 0.233 ± 0.006*
Resveratrol (60 mg/kg) 0.243 ± 0.007*
Depression was induced by acute reserpine injection. Statistical analysi
multiple comparisons test. Data were expressed as mean ± SEM, n= 8
* Signiﬁcant from depressed control at P< 0.05.
# Signiﬁcant from normal control at P< 0.05.3.5. Effect of trans-resveratrol on the liver GSH and MDA levels
Results are illustrated in Table 3. Acute reserpine injection sig-
niﬁcantly decreased the GSH content and increased the MDA
level compared to the vehicle control. Fluoxetine (24 mg/kg,
p.o) showed a signiﬁcant increase in the GSH content and
decrease in the MDA level. Trans-resveratrol at the higher
two doses showed better results where the dose of trans-resvera-
trol (60 mg/kg, p.o.) normalized both theGSHandMDA levels.
3.6. Histopathological examination
Results are represented in Fig. 3a–f. Histopathological exami-
nation of the liver sections revealed that induction of depres-
sion by reserpine resulted in slight hydropic degeneration of
the hepatocytes. Neither ﬂuoxetine nor any of the three resve-
ratrol doses used showed any histopathological changes in the
hepatocytes.
4. Discussion
This study was designed to investigate the antidepressant and
hepatoprotective effects of resveratrol against ﬂuoxetine in anin depressed rats using the acute reserpine injection model of
Norepinephrine (lg/g tissue) Dopamine (lg/g tissue)
0.116 ± 0.012* 0.427 ± 0.03*
0.085 ± 0.001# 0.359 ± 0.02#
0.121 ± 0.005* 0.480 ± 0.02*
0.093 ± 0.001# 0.439 ± 0.02*
0.096 ± 0.001# 0.473 ± 0.01*
0.108 ± 0.001* 0.476 ± 0.01*
s was carried out by one way ANOVA followed by LSD post hoc
rats/group.
Table 3 Effect of trans-resveratrol on the liver GSH and MDA levels in depressed rats using the acute reserpine injection model of
depression.
Antioxidant parameter GSH (lmol/g tissue) MDA (nmol/g tissue)
Groups
Normal control 13.24 ± 0.53* 29.4 ± 1.4*
Depressed control 8.81 ± 0.18# 41.62 ± 2.12#
Fluoxetine (24 mg/kg) 10.40 ± 0.85*,# 35.82 ± 1.17*,#
Resveratrol (15 mg/kg) 9.01 ± 0.7# 37.3 ± 2.67#
Resveratrol (30 mg/kg) 11.09 ± 0.38*,# 34.74 ± 1.73*
Resveratrol (60 mg/kg) 11.99 ± 0.35* 30.57 ± 2.48*
Depression was induced by acute reserpine injection. Statistical analysis was carried out by one way ANOVA followed by LSD multiple
comparison test. Data were expressed as mean ± SEM, n= 8 rats/group.
* Signiﬁcant from depressed control at P< 0.05.
# Signiﬁcant from normal control at P< 0.05.
Figure 3 (a) Liver of rat from the normal control group showing no histopathological changes (H& E x 400). (b) Liver of rat from the
depressed group showing slight hydropic degeneration of hepatocytes (H& E x 400). (c) Liver of rat from the Fluoxetine group showing no
histopathological changes (H& E x 400). (d) Liver of rat from the Resveratrol 15 group showing no histopathological changes (H& E x
400). (e) Liver of rat from the Resveratrol 30 group showing no histopathological changes (H& E x 400). (f) Liver of rat from the
Resveratrol 60 group showing no histopathological changes (H& E x 400).
Hepatoprotective and antidepressant effects of resveratrol 195
196 R.F. Ahmed et al.acute reserpine model of depression in rats. Soon after the
introduction of reserpine, it became apparent that the drug
could induce depression in patients being treated for hyperten-
sion as well as in normal subjects. Reserpine model is based on
the capability of antidepressants to reverse the depressive-like
effects of reserpine in rodents.28–30 Reserpine induces in rats a
behavioral and biochemical syndrome that has been exten-
sively studied as a potential animal model of depression.31–33
Qingjun et al. reported that i.p. injection of reserpine increased
ﬂoating time in the Porsolt swim test in a dose- and time-
dependent manner in rats.34 Moreover, reserpine was found
to induce a syndrome of locomotor hypomotility in the open
ﬁeld test and an increase in the immobility period in the tail
suspension test (TST).35–37 Subsequent research in rats showed
that reserpine-induced behavioral depression was correlated to
the depletion of brain monoamines. However, although the
concentrations of norepinephrine (NE), dopamine (DA), and
serotonin (5-HT) in brain remained at low levels for more than
a week after acute reserpine treatment (5 mg/kg), the behav-
ioral depression usually ended in 72 h.18 Furthermore, bio-
chemical analysis revealed that chronic reserpine treatment
signiﬁcantly induced lipid peroxidation, decreased GSH level
as well as the levels of antioxidant defense enzymes; superoxide
dismutase (SOD) and catalase (CAT) in rat brain tissues.38–40
In the present investigation, reserpine resulted in a signiﬁ-
cant hypo-locomotor activity in the open ﬁeld test and also a
pronounced increase in the immobility duration in the forced
swimming test as compared to vehicle control. Moreover, a
signiﬁcant decrease in the brain neurotransmitters was
recorded as well as a signiﬁcant increase in the brain and liver
MDA level. On the other hand, acute injection of reserpine
only caused a signiﬁcant decrease in the liver GSH without
affecting brain GSH content.
Trans-resveratrol (60 mg/kg, p.o.) reversed reserpine-
induced hypo-motility in the open ﬁeld test and forced swim-
ming test in a manner comparable to that of ﬂuoxetine. These
ﬁndings are in rhythm with former investigations.17,41 In addi-
tion trans-resveratrol reversed the reserpine-induced reduction
in the brain neurotransmitter content. Previous studies showed
that resveratrol is an inhibitor of norepinephrine and 5-HT
uptake activity in rats.42 Recent researches also indicated that
trans-resveratrol inhibits monoamine oxidase (MAO)
activity.17
Many studies have focused on the adverse effects of ﬂuox-
etine exposure on the liver in both patients and animal models.
Elevated levels of aminotransferases, hepatocellular changes
and acute hepatitis have been observed among animals as
well as patients treated with ﬂuoxetine in clinical trials.4,43
Thompson et al. (2000) have shown that one of ﬂuoxetine’s
metabolites, 4-triﬂuoromethylphenol decreases intracellular
glutathione concentration in liver slices.44 However, Zaﬁr
and Banu observed no changes in the antioxidant defense
components and oxidative stress markers in the liver of
non-stressed rats exposed to 20 mg ﬂuoxetine/kg for 21 days.
Moreover; they ascertained that treatment with ﬂuoxetine
ameliorates stress-induced oxidative damage.45 On the other
hand, Adachi et al. reported that; hepatic dysfunction was con-
ﬁrmed by a signiﬁcant increase in liver enzyme activities and
uric acid concentration in liver of ﬂuoxetine treated rats pro-
viding an evidence for the pathogenic role of ﬂuoxetine in
inducing oxidative liver injury.46 In the present study, ﬂuoxe-
tine ingestion for 3 days following induction of depression byreserpine, normalized the brain MDA level and resulted in a
signiﬁcant decrease in liver MDA level and signiﬁcant increase
in the GSH level compared to the depressed group.
On the other hand, trans-resveratrol; previously reported as
hepatoprotective,47–49 normalized the brain and liver MDA
level and liver GSH content and it is worth mentioning that
results obtained from the 60 mg/kg dose level were better than
those obtained from ﬂuoxetine.
5. Conclusion
Results revealed that acute ingestion of resveratrol (60 mg/
kg bwt) for 3 days after induction of depression by reserpine,
showed a hepatoprotective and an antidepressant-like effects
comparable to those of ﬂuoxetine. Further investigations are
required to evaluate long term efﬁcacy and safety of resvera-
trol as antidepressant.6. Conﬂict of interest
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